EE200000355A - IFN/IFNAR kompleks ja vastav molekul ning nende kasutamine, DNA, peremeesrakk, liitvalgu valmistamismeetod, I tüüpi IFN säilimisaja pikendamise meetod, farmatseutiline kompositsioon ja IFNAR kasutamine - Google Patents

IFN/IFNAR kompleks ja vastav molekul ning nende kasutamine, DNA, peremeesrakk, liitvalgu valmistamismeetod, I tüüpi IFN säilimisaja pikendamise meetod, farmatseutiline kompositsioon ja IFNAR kasutamine

Info

Publication number
EE200000355A
EE200000355A EEP200000355A EEP200000355A EE200000355A EE 200000355 A EE200000355 A EE 200000355A EE P200000355 A EEP200000355 A EE P200000355A EE P200000355 A EEP200000355 A EE P200000355A EE 200000355 A EE200000355 A EE 200000355A
Authority
EE
Estonia
Prior art keywords
ifnar
ifn
dna
pharmaceutical composition
host cell
Prior art date
Application number
EEP200000355A
Other languages
English (en)
Estonian (et)
Inventor
Tepper Mark
Cunningham Mark
Sherris David
El Tayar Nabil
Mckenna Sean
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200000355A publication Critical patent/EE200000355A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EEP200000355A 1997-12-19 1998-12-18 IFN/IFNAR kompleks ja vastav molekul ning nende kasutamine, DNA, peremeesrakk, liitvalgu valmistamismeetod, I tüüpi IFN säilimisaja pikendamise meetod, farmatseutiline kompositsioon ja IFNAR kasutamine EE200000355A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6829597P 1997-12-19 1997-12-19
PCT/US1998/026926 WO1999032141A1 (en) 1997-12-19 1998-12-18 Ifnar2/ifn complex

Publications (1)

Publication Number Publication Date
EE200000355A true EE200000355A (et) 2001-10-15

Family

ID=22081665

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000355A EE200000355A (et) 1997-12-19 1998-12-18 IFN/IFNAR kompleks ja vastav molekul ning nende kasutamine, DNA, peremeesrakk, liitvalgu valmistamismeetod, I tüüpi IFN säilimisaja pikendamise meetod, farmatseutiline kompositsioon ja IFNAR kasutamine

Country Status (28)

Country Link
US (1) US6372207B1 (xx)
EP (1) EP1037658B1 (xx)
JP (1) JP4601163B2 (xx)
KR (1) KR100593981B1 (xx)
CN (1) CN1241638C (xx)
AR (1) AR020315A1 (xx)
AT (1) ATE218362T1 (xx)
AU (1) AU755078B2 (xx)
BG (1) BG64920B1 (xx)
BR (1) BR9813753A (xx)
CA (1) CA2311648C (xx)
DE (1) DE69805844T2 (xx)
DK (1) DK1037658T3 (xx)
EA (1) EA003635B1 (xx)
EE (1) EE200000355A (xx)
ES (1) ES2174530T3 (xx)
HK (1) HK1032914A1 (xx)
HU (1) HUP0100456A3 (xx)
IL (2) IL136855A0 (xx)
NO (1) NO20002691L (xx)
NZ (1) NZ504771A (xx)
PL (1) PL197568B1 (xx)
PT (1) PT1037658E (xx)
SK (1) SK9222000A3 (xx)
TR (1) TR200001961T2 (xx)
UA (1) UA74132C2 (xx)
WO (1) WO1999032141A1 (xx)
ZA (1) ZA9811634B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation
US7138379B2 (en) 2000-07-26 2006-11-21 Schering Aktiengesellschaft Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
IL147414A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev Ifnar2 mutants, their production and use
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
PL1666496T3 (pl) * 2003-08-25 2014-08-29 Toray Industries Kompozyt interferonu beta
CN100400664C (zh) * 2005-09-06 2008-07-09 中国人民解放军第四军医大学 肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法
EP2572734B1 (en) * 2006-10-31 2016-04-06 East Carolina University Cytokine-based fusion proteins for treatment of immune disorders
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
EP3348275A3 (en) 2009-03-31 2018-10-24 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
KR101293363B1 (ko) * 2011-02-28 2013-08-05 성균관대학교산학협력단 인터페론 수용체 유전자를 포함하는 조류독감 예방용 조성물
MX366124B (es) * 2013-03-15 2019-06-27 Janssen Biotech Inc Anticuerpos antagonistas del interferón alfa y omega.
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
KR20200015742A (ko) * 2017-06-20 2020-02-12 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 암 치료를 위한 인터페론 전구약물
AU2018321359B2 (en) 2017-08-22 2023-11-30 Sanabio, Llc Soluble interferon receptors and uses thereof
CN112646783B (zh) * 2020-12-30 2023-12-01 广州医科大学附属市八医院 表达基因、经基因修饰的受精卵的构建方法和小鼠模型的构建方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821078A (en) 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
IL106591A (en) 1992-09-03 2008-03-20 Yeda Res & Dev Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it
IL107378A (en) 1993-10-24 2005-05-17 Yeda Res & Dev SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE

Also Published As

Publication number Publication date
EA003635B1 (ru) 2003-08-28
BG64920B1 (bg) 2006-09-29
US6372207B1 (en) 2002-04-16
NO20002691D0 (no) 2000-05-25
DE69805844T2 (de) 2002-10-24
CN1282255A (zh) 2001-01-31
WO1999032141A1 (en) 1999-07-01
PT1037658E (pt) 2002-10-31
IL136855A0 (en) 2001-06-14
IL136855A (en) 2007-07-24
KR20010032836A (ko) 2001-04-25
PL197568B1 (pl) 2008-04-30
HK1032914A1 (en) 2001-08-10
EP1037658B1 (en) 2002-06-05
AU1926999A (en) 1999-07-12
NZ504771A (en) 2002-09-27
EA200000685A1 (ru) 2000-12-25
AR020315A1 (es) 2002-05-08
AU755078B2 (en) 2002-12-05
DK1037658T3 (da) 2002-09-30
PL341423A1 (en) 2001-04-09
NO20002691L (no) 2000-08-18
BG104539A (en) 2001-04-30
SK9222000A3 (en) 2001-01-18
ES2174530T3 (es) 2002-11-01
TR200001961T2 (tr) 2000-11-21
BR9813753A (pt) 2000-10-10
ATE218362T1 (de) 2002-06-15
CN1241638C (zh) 2006-02-15
JP2001526242A (ja) 2001-12-18
KR100593981B1 (ko) 2006-06-30
DE69805844D1 (de) 2002-07-11
HUP0100456A3 (en) 2003-09-29
CA2311648C (en) 2010-11-16
UA74132C2 (uk) 2005-11-15
HUP0100456A1 (hu) 2001-06-28
JP4601163B2 (ja) 2010-12-22
ZA9811634B (en) 1999-06-22
CA2311648A1 (en) 1999-07-01
EP1037658A1 (en) 2000-09-27

Similar Documents

Publication Publication Date Title
EE200000355A (et) IFN/IFNAR kompleks ja vastav molekul ning nende kasutamine, DNA, peremeesrakk, liitvalgu valmistamismeetod, I tüüpi IFN säilimisaja pikendamise meetod, farmatseutiline kompositsioon ja IFNAR kasutamine
EE200000151A (et) Aminoterminaalselt kärbitud rantes vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
EP2277889A3 (en) Fusion proteins of albumin and interferon beta
WO2001012659A3 (en) Human dna sequences
DE59812907D1 (de) Substituierte Isochinolin-3-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
PL324328A1 (en) Novel nucleic acid construct, method of obtaining same, application thereof, method of manufacturing a pharmaceutic agent, method of producing cells, method of producing protein and pharmaceutic agent as such
BR9401321A (pt) Muteína, sequência de DNA, vetor, célula, sequência de RNA composto, processo para sua preparação, composição farmacêutica e uso.
NO20010277D0 (no) Benzocykloheptener, fremgangsmåte for fremstilling derav, farmasöytiske preparater inneholdende disse, og deres anvendelse for fremstilling av medikamenter
FR2723951B1 (fr) Peptide, agent antibacterien contenant ce peptide, gene de ce peptide, adn recombine contenant ce gene et procede de preparation de ce peptide.
NO984352D0 (no) Trisykliske forbindelser med aktivitet spesifikt for integriner, i sµrdeleshet <alfa>v<beta>3 integriner, metode for fremstilling av disse, mellomprodukter derfor, anvendelse for angitte forbindelser som legemidler, og farmas°ytiske preparater i
IT1291366B1 (it) Composizione farmaceutica antivirale comprendente acido glicirrizico ed almeno una proteina dotata di attivita' antivirale
DK1117661T3 (da) Propanolaminderivater substitueret med heterocycliske grupper, fremgangsmåde til deres fremstilling, farmaceutiske præparater indeholdende disse forbindelser og deres anvendelse
DE69731646D1 (de) Verabreichung von nukleinsäurepartikeln
DE60037978D1 (de) Interferon ähnliche moleküle, und deren verwendungen
EE04812B1 (et) 2-fenüülpüraan-4-ooni derivaadid, nende valmistamismeetod ja kasutamine, vaheühendite kasutamine jafarmatseutiline kompositsioon
CA2032167A1 (en) Dna coding for protein binds to enhancer of.alpha.-fetoprotein gene
BR9812138A (pt) Métodos e composições para terapias empregando genes codificando proteìnas segregadas tal como interferon-beta
FI960308A0 (fi) Menetelmä Haemophilus influenzae, tyyppi b:n P2-proteiinien ilmentämiseksi ja puhdistamiseksi
DE69823225D1 (de) Fusionsproteine, bestehend aus proteinaseinhibitoren
BR9606521A (pt) Polinucleotídeo purificado e isolado molécula de dna construção de expressão de dna célula hospedeira método para produzir um polipeptídeo humano polipeptídeo purificado e isolado anticorpo e linhagem celular de hibridoma
DE60009858D1 (de) Hydrolysate aus Proteinen von Schwämmen und Verfahren zur deren Herstellung
DE3685044D1 (de) Analoge interferon-polypeptide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DK0676413T3 (da) Inteferon-alfa/beta-bindingsprotein, dets fremstilling og anvendelse
DE69738977D1 (de) Neues fusionsprotein, dafuer kodierendes gen, rekoerwendung
FR2761992B1 (fr) Nouveaux steroides 4-halogenes, leur procede et intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner